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ABSTRACT
Background. Limited data are available regarding outcomes in
elderly headandneckcancer patients.This retrospective study
was designed to characterize head and neck cancer in geriatric
patients.
PatientsandMethods. This study includedallpatients ina large
university-based tumor registrywhowere diagnosedwith head
and neck cancer from January 1, 1990, to December 31, 2005.
Patients aged $70 years at the time of diagnosis were de-
fined as older. Overall survival and progression-free survival
were censored at 60months. Survival differences were com-
pared using the log-rank test. Hazard ratios were estimated
using a Cox proportional hazards model, adjusting for po-
tential confounders.
Results. Of1,598patients identified, 1,166patientswere aged
,70 years (i.e., younger) and 281 patients were aged $70
years (older).Whencontrolling for possible confounders, older
patientswerenearly twice as likely todiewithin5years as their
younger counterparts (hazard ratio: 1.92). The median life
expectancy for older patients was nearly 5 years for stage I–II
disease and,2 years for stage III–IV disease. Older patients
with stage III–IVdiseasewho receivedmultimodality therapy
had 5-year survival similar to that younger patients with
stage III–IV disease who were treated similarly (33.2% vs.
44.0%). Older patientswith stage III–IV diseasewho received
single-modality therapy had extremely poor survival com-
pared with all other patients (hazard ratio for progression-
free survival: 1.5).
Conclusion.This study highlights the need for better un-
derstanding of the factors affecting head and neck cancer
outcomes in elderly patients. Information about life expec-
tancy in elderly head and neck cancer patients may help guide
treatment decisions. The Oncologist 2015;20:159–165
Implications forPractice: In this studywedemonstratethatelderlypatientswithearly stageheadandneckcancerdid justaswell as
younger patients in termsof cancer outcomes but had increasedmortality fromother causes. In patients at advanced stage, those
treated in a stage-appropriate manner with multimodality therapy had overall survival similar to that of younger patients. This
study demonstrated age as an independent predictor of survival in head and neck cancer. It also highlighted the need for better
understanding of factors that preclude the delivery of stage-appropriate care in elderly patients with head and neck cancer.
INTRODUCTION
Cancers of the head and neck are the fifth most common
cancer worldwide and responsible for more than 200,000
deaths per year [1]. More than 50% of head and neck cancer
cases occur in patients aged $60 years, and 28% occur in
patients aged $70 years. With an aging population, we will
likely face increasing numbers of elderly head and neck cancer
patients in the coming years. Despite this, few studies have
focused specifically on the characteristics and treatment of
older patients with squamous cell carcinoma of the head and
neck (HNSCC). Of those studies that exist, several have shown
that elderly patients can achieve outcomes similar to those of
youngerpatients if treatedwith similar therapies [2–9].Others
have noted worse outcomes in older patients but have
concluded that the higher risk of mortality is entirely due to
higher comorbidity status and competing causes of mortality
rather than chronological age [10, 11], whereas others have
suggested that age is an independent prognostic variable
[11, 12]. Multiple studies have also concluded that geriatric
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patients with head and neck cancer frequently receive
nonstandard and less aggressive therapies than their younger
counterparts [13–15]. Receiving nonstandard therapy is an
independent risk factor for decreased survival [16, 17].
Despite the encouragingly similar outcomes and rates of
adverse treatment effects between elderly and younger patients
in some studies [18–20], other investigators identified higher
rates of complications in older patients [21, 22]. In addition,
cancer clinical trials regularly underrepresent older patients
[23–25], and little progress has beenmade to expand enrollment
of the elderly into trials over the past 10 years [26, 27]. As long as
there is a paucity of clinical trial data available to determine
standard management for elderly patients, many may continue
to receive nonstandard or suboptimal treatment.
Physicians treating elderly patients with HNSCC are faced
witha lackofdata regardingwhatconstitutes an “elderly”patient
andwhether to seekcurative treatment, consideringpatientage.
More studies are needed to assess real-world outcomes of older
patients with HNSCC to provide improved guidance for physicians
and patients regarding when and how to treat. The purpose of
this retrospective analysis is to more clearly characterize how
outcomes in head and neck cancer compare between a large
group of older patients and their younger counterparts.
METHODS
Data Source
Study-related retrospective data were obtained from the
University of North Carolina (UNC) Cancer Registry, which
contains information regarding all patients who are diagnosed
with cancer and/or receive cancer-directed therapy at UNC
hospitals. The registry includes information on demographics,
primary tumorsite,presenceofmultipleprimary tumors, tumor
morphology, stage at diagnosis, treatment, relapse, mortality,
and date of last contact. Once enrolled in the registry, all
patients are contacted yearly for the remainder of their lives.
Losses to follow-up are queried against death records including
the Social Security Death Index and other sources.
Study Population
Study patients included all patients in theUNCCancer Registry
diagnosed between January 1, 1990, and December 31, 2005,
with head and neck cancer. This study was approved by
the institutional review board (IRB) of the University of
North Carolina (IRB number 10-0952). Patients were grouped
according to site. Site groups considered included larynx,
oropharynx (including tonsil, base of tongue, soft palate), oral
cavity (including floor of mouth, buccal mucosa, hard palate,
gum, lip, and anterior two-thirds of tongue), and hypopharynx
(including pyriform sinus).
Patients were also grouped according to treatment cate-
gory. Treatment categories considered were surgery only, chemo-
therapy only, radiation only, surgery then radiation, radiation then
surgery, surgery followed by chemotherapy and radiation, chemo-
radiation, chemoradiation with salvage surgery, no treatment/
palliative care only/hospice, and other (including patients who
received no treatment and those for whom treatment modalities
or intent of treatment was unknown). Tumor registry data were
supplemented with chart review in cases for which treatment cat-
egories were ambiguously coded in the tumor registry. To further
simplify analysis, surgery then radiation and radiation then surgery
were condensed into surgery and radiation. Chemoradiation with
salvage surgery and surgery then chemoradiationwere placed into
the other category because of the small numbers of patients
in those categories.
Patients with American Joint Committee on Cancer (AJCC)
version 7 stage IVC cancer, including all patients with distant
metastasis, were excluded fromanalysis to focus on outcomes in
patientswith local-regional tumorstypically treatedwithcurative
intent (stages I–IVB). Patients whose stage information was not
available in the database were excluded. Histologic tumor types
excluded to avoid confounding the results include benign
tumors, carcinoma in situ, salivary gland tumors, sarcomas,
teratomas, Kaposi sarcoma, and lymphomas.
Fromall data fields in the registry, the following itemswere
evaluated in the current analysis because of known or
suspected association with HNSCC outcomes: age, sex, race,
smokingstatus, alcoholuse, sitegroup,histologic type, stageat
diagnosis, treatment category, relapse, andmortality. For age,
patients were divided into 2 groups: $70 years (older) and
,70 years (younger). Recurrence times were calculated from
the date of initial diagnosis to the date of recurrence recorded
in thedatabase. Patients lost to follow-upwerecensoredat the
date of last information entry into the database, whether that
was the last date of phone contact or last visit.
In addition to the review of cancer registry data, a selective
chart review was conducted that focused on elderly patients
with advanced larynx cancer receiving unimodality therapy. The
intent of this secondary review was to determine factors that
may have precluded this group from receiving multimodality,
stage-appropriate therapy. Patient comorbidity data were col-
lected. The initial treatment recommendation, the actual treat-
ment received, and treatment mortality were assessed.
Statistical Analysis
All statistical analysis was performed using R version 2.13.1
software (http://cran.r-project.org). Baseline characteristics
of patients from each group (younger and older) were
compared using a chi-square test for categorical variables
and one-way analysis of variance for continuous variables
between younger and older patients. Overall survival (OS)was
calculated fromthedateofdiagnosis to timeofdeathordateof
last follow-up. Progression-free survival (PFS) was calculated
from the date of diagnosis to time of first recurrence or death.
Both OS and PFS were censored at 60 months. A log-rank test
was used to compare survival differences in different age
groups. A Cox proportional hazards model was used to
estimate the hazard ratio (HR). Factors adjusted for in the
multivariate analysis included age, sex, race, smoking status,
alcohol use, stage, site, and treatment. These include known
risk factors for head and neck cancer [9, 28, 29] and those
variables that differed by age group on univariate analysis. All
tests were two-sided with a significance cutoff of .05.
RESULTS
Demographics
A total of 1,447 HNSCC patients (1,166 younger patients, 281
older patients) were identified for inclusion in this study.
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Comprehensive demographic information is shown in Table 1.
The median age for the older group was 75 years. Patients in
thisgroupweremore likely tobe female,white,diagnosedwith
lower stage cancer, previous smokers, andneverdrinkers. Site-
related categorization indicates that older patientsweremuch
more likely tohaveoral cavitycancer (32%vs.19%,p, .01)and
less likely tohaveoropharyngeal cancer (22%vs. 36%,p, .01).
Combined surgery and radiation therapy was the most
frequent treatment among both age categories. In addition,
younger patients were more likely than older patients to
receive chemotherapy and radiation together.
Univariate Survival Analysis
In the univariate analysis, age $70 years was significantly
associated with an increased risk of death (HR: 1.51; 95%
confidence interval [CI]: 1.29–1.78) (Table 2). In addition to
age, the univariate analysis confirmed prior reports of
unfavorable outcomes including worse OS and PFS associated
with nonwhite race, male sex, any history of alcohol use, any
history of smoking, having cancer of the hypopharynx, and
having higher stage cancer (Table 2). A small number of
patients included in the study (,2%) were treated with
palliative intent (chemotherapy only) despite having AJCC
staging that would generally be treated for cure. Such patients
generally had unusual circumstances or comorbidities and
experienced statistically significantly worse outcomes (HR for
OS: 3.15; 95% CI: 1.85–5.36).
Multivariate Survival Analysis
To adjust for confounding effects of known risk factors on the
impact of age, multivariate analysis was performed (Table 2).
After controlling for other factors, the negative impact of age
on outcomes was increased. Review of the data reveals that
increasing age is associated with earlier stage tumors,
especially in oral cavity cancers. Accordingly, controlling for
stage unmasked evenmore risk associatedwith advanced age.
When controlling for confounders, older patients were nearly
twice as likely to die (HR: 1.92; 95% CI: 1.62–2.28; p, .0001)
and 70% more likely to die or relapse compared with their
youngercounterparts (HR:1.68;95%CI:1.43–1.97;p, .0001).
In the multivariate analysis, many covariates remained
statistically significant, including race, smoking status, tumor
stage, tumor site, and treatment modality. As expected,
increased risk associated with multimodality therapy seen in
the univariate analysis disappears after controlling for stage.
Patients receiving radiation therapy alone continued to have
considerably poorer outcomes compared with patients re-
ceiving surgery alone.Thismay be explained by treatment bias
directing patients unfit for surgery, and presumably sicker
overall, to radiation only.
Subgroup Analysis
The finding of worse outcomes in older patients in the
univariate analysis was expected from prior literature. Based
on Kaplan-Meier modeling, patients aged $70 years at
diagnosis had median OS of 35 months (95% CI: 28–41
months), whereas younger patients had median OS of 60
months (95%CI: 55–68months;p, .0001).Olderpatients had
shorter median PFS at 25 months (95% CI: 20–32 months) in
comparison with the younger cohort, with median PFS of 44
months (95% CI: 38–52 months; p , .0001). The median life
expectancy for elderly patients with early stage cancer was
nearly 5 years (56 months: 95% CI: 38–71months). The HR for
death or relapse in the older cohort was 51% higher than in
younger patients. Consequently, we turned our attention to
possible interactions between age, stage, intensity of treat-
ment, and adverse outcomes to better understand this
unexpected finding.
Weconsideredwhether pooreroutcomes inolder patients
might be related to physicians systematically offering less
intensive therapy. In this analysis, therapy was simplified to
unimodality (surgery or radiation alone) or multimodality
Table 1. Characteristics of younger (aged,70 years) and




(n5 1,166), n (%)
Aged ‡70 years
(n5 281), n (%)
Sex
Female 268 (23) 106 (38)a
Male 898 (77) 175 (62)
Race
White 707 (61) 229 (81)a
Black 426 (36) 47 (17)
Other 33 (3) 5 (2)
Smoking status
Current 535 (46) 75 (27)a
Previous 185 (16) 73 (26)
Never 73 (6) 26 (9)
Unknown 373 (32) 107 (38)
Alcohol use
Current 378 (32) 68 (24)a
Past 215 (18) 34 (13)
Never 178 (16) 71 (25)
Unknown 395 (34) 108 (38)
Stage
I 174 (15) 69 (25)a
II 173 (15) 55 (19)
III 189 (16) 47 (17)
IV 630 (54) 110 (39)
Site
Hypopharynx 110 (9) 26 (9)a
Larynx 356 (31) 86 (30)
Oral cavity 219 (19) 89 (32)
Oropharynx 422 (36) 61 (22)
Other 59 (5) 19 (7)
Treatment
Surgery only 147 (13) 35 (12)a
Radiation only 175 (15) 61 (22)
Chemotherapy plus
radiation
271 (23) 26 (9)
Surgery plus
radiation
380 (32) 104 (37)
Chemotherapy only 30 (3) 1 (0)
Other 163 (14) 54 (19)
ap, .01.
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(surgery plus radiation or chemotherapy plus radiationwith or
without surgery) with the expectation that most patients with
early stage disease (stage I or II) could be managed with
unimodality therapy, whereas most with later stage disease
(stage III or IV) should receive multimodality therapy. Because
ofconcernsabout interactionbetween therapyandsite (which
vary between younger and older patients), we limited the
analysis to patients with cancer of the larynx for tumor
homogeneity, commoncause (smoking) amongbotholderand
younger patients, and large size of the treatment category.
There was no difference in the rates of single- and multi-
modality therapy as a function of age and stage (Table 3).
We then evaluated survival outcomes as a function of age
and treatment intensity stratified by early versus late stage for
the entire data set. Among early stage patients, older patients
had worse OS and PFS (Fig. 1). For early stage patients within
bothagegroups,patientsonmultimodality therapydid slightly
worse, although this was not statistically significant. This is
consistent with the possibility that the patients treated with
multimodality therapy had higher risk diseasewithin the stage
Table 2. Analysis of overall and progression free survival hazard ratios
Patient characteristics
Univariate analysis Multivariate analysisa
OS, HR (95% CI) PFS, HR (95% CI) OS, HR (95% CI) PFS, HR (95% CI)
Age
,70 years 1 (reference) 1 (reference) 1 (reference) 1 (reference)
$70 years 1.512 (1.29–1.78)d 1.44 (1.23–1.68)d 1.92 (1.62–2.28)d 1.68 (1.43–1.97)d
Sex
Female 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Male 1.22 (1.04–1.43)b 1.14 (0.98–1.32) 1.10 (0.93–1.30) 1.07 (0.92–1.25)
Race
White 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Black 1.357 (1.18–1.57)d 1.21 (1.05–1.39)c 1.26 (1.09–1.47)c 1.14 (0.99–1.31)
Other 1.44 (0.96–2.15) 1.39 (0.95–2.05) 1.76 (1.17–2.65)c 1.65 (1.11–2.43)b
Smoking status
Never 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Other 2.20 (1.58–3.08)d 1.76 (1.33–2.34)d 1.81 (1.27–2.57)c 1.54 (1.13–2.08)c
Alcohol use
Never 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Other 1.43 (1.18–1.74)d 1.25 (1.05–1.49)b 1.16 (0.94–1.43) 1.08 (0.89–1.31)
Stage
Early (I and II) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Late (III and IVA–B) 2.08 (1.78–2.45)d 1.68 (1.46–1.95)d 2.08 (1.75–2.47)d 1.77 (1.52–2.08)d
Site
Hypopharynx 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Oropharynx 0.62 (0.50–0.78)d 0.68 (0.54–0.84)d 0.74 (0.59–0.93)b 0.77 (0.61–0.96)b
Other 0.48 (0.38–0.59)d 0.60 (0.48–0.74)d 0.61 (0.49–0.76)d 0.72 (0.58–0.90)c
Treatment
Surgery only 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Radiation only 1.69 (1.30–2.20)d 1.65 (1.29–2.09)d 1.48 (1.13–1.95)c 1.52 (1.19–1.96)d
Chemotherapy plus radiation 1.62 (1.27–2.07)d 1.38 (1.10–1.73)c 1.08 (0.83–1.40) 1.05 (0.82–1.34)
Surgery plus radiation 1.40 (1.10–1.80)c 1.26 (1.01–1.57)b 1.13 (0.88–1.44) 1.08 (0.86–1.36)
Chemotherapy only 3.15 (1.85–5.36)d 2.51 (1.49–4.24)d 2.23 (1.29–3.83)c 2.04 (1.19–3.49)c
Other 1.70 (1.29–2.23)d 1.85 (1.44–2.37)d 1.52 (1.14–2.01)c 1.76 (1.36–2.28)d




Abbreviations: CI, confidence interval; HR, hazards ratio; OS, overall survival; PFS, progression-free survival.






n (%) p value
Early stage (I and II)
Unimodality therapy 80 (57.1) 25 (52.1) .7593
Multimodality therapy 39 (27.9) 14 (29.2)
Late stage (III and IV)
Unimodality therapy 67 (27.3) 10 (23.3) .1886
Multimodality therapy 163 (66.5) 27 (62.8)
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grouping.Although incompletedata limited theuseof relapse-
free survival as a primary outcome, investigation of relapse in
early stage patients showed that older and younger patients
relapsed at the same rate, suggesting the difference in OS and
PFS was primarily due to noncancer competing causes of
mortality.
When considering patients at advanced stages, a striking
difference was detected in outcomes by unimodality versus
multimodality therapy. Older patients treated with multi-
modality therapy demonstrated outcomes essentially identi-
cal to those of younger patients (Fig. 2). However, older
patients treated with unimodality therapy had dismal out-
comes overall compared with all other patients (HR for PFS:
1.5; 95% CI: 1.19–1.89). Each of the major anatomic subsites
were evaluated independently with entirely consistent results
(data not shown). Five-year survival for older patients with
advanced stage cancers who received multimodality therapy
was slightly lower than for younger patients (33.2% vs. 44.0%,
p 5 .0522), although the difference was not statistically
significant.
In a final analysis, we questioned whether older patients
treated with unimodality therapy outperformed patients who
received no curative therapy at all. Among older patients
with late-stage disease, the HR for death within 5 years for
those receiving no therapy or palliative care only compared
with those receiving unimodality therapy was 1.69 (95% CI:
1.17–2.45; p 5 .0051), supporting a survival advantage with
unimodality therapy over no therapy.
Selective Chart Review: Older Patients With Advanced
Larynx Cancer Treated With Unimodality Therapy
We identified 24 older patients with advanced larynx cancer
who were treated with unimodality therapy. We noted that
the majority had multiple comorbidities including cardiac
arrhythmias, severe coronary artery disease, previous myo-
cardial infarction,diabetesmellitus, depression, hypertension,
chronic renal failure, peripheral vascular disease, dementia,
morbid obesity, and psychosis. Furthermore, the majority
(75%) received an initial recommendation for multimodality
therapy. Ultimately, 63% were treated with surgery alone and
37% received radiation alone. Among these patients, 50%
declined secondary therapy and 17% died within the first
5 months after diagnosis.
DISCUSSION
In this study we sought to determine the impact of advanced
age on treatment and oncologic outcomes in patients with
head and neck cancer. We noted a significant association
between advanced age at presentation and survival: patients
aged $70 years were nearly 50% more likely to die and 45%
Figure 1. Kaplan-Meier survival plots for all patientswith early stage disease (stages I and II) by age group (younger vs. older) and therapy
(unimodality versus multimodality). (A): Overall survival. (B): Progression-free survival.
Abbreviations: MT, multimodality therapy; OG, older group; UT, unimodality therapy; YG, younger group.
Figure2. Kaplan-Meier survivalplots forall patientswith late-stagedisease (stages III and IV)byagegroup(youngervs.older) andtherapy
(unimodality versus multimodality). (A): Overall survival. (B): Progression-free survival.
Abbreviations: MT, multimodality therapy; OG, older group; UT, unimodality therapy; YG, younger group.
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more likely to recur within 5 years of diagnosis compared with
their younger counterparts. However, we also demonstrated
that older patients receiving stage-appropriate treatment for
early and late stage cancer hadoncologic outcomes equivalent
to those of their younger counterparts.These findings suggest
that advanced age alone should not preclude patients from
receiving stage-appropriate therapy. Given the paucity of
clinical trials assessing the impactofadvancedageonheadand
neckcanceroutcomes,our findingsprovidevaluable insight for
patients and clinicians about the appropriate treatment of
elderly patients with head and neck cancer.
The results from our study support the use of stage-
appropriate therapy for elderly head and neck cancer patients
with both early and advanced-stage disease. Although older
patients with early stage head and neck cancer demonstrated
significantly worse overall survival compared with younger
patients, no significant difference in rates of cancer recurrence
was noted between older and younger patients. This suggests
that the elevated risk of death in the older cohort was
attributable in large part to competing causes ofmortality.We
conclude that most elderly patients with early stage disease
should be treated in a stage-appropriate manner and should
experience similarly favorable oncologic outcomes when
compared with younger patients.
Among patients with late-stage disease, we observed that
older patients treated with stage-appropriate multimodality
therapy had outcomes comparable to those of younger
patients of similar stage. Competing causes of death likely
represented a smaller overall contribution to adverse out-
comes in this group because cancer is the primary cause of
death in patients with late-stage head and neck cancer. These
findings are consistent with a retrospective review of patients
aged.70 years undergoing concomitant chemoradiation for
locally advanced head and neck cancer by Maggiore et al. [9]
They demonstrated a 5-year survival of 32% and found that
86.5% of patients were able to complete all treatment cycles
[9]. Although multimodality therapy appears to provide
a survival advantage in appropriately selected patients aged
.70 years, our results also demonstrate the benefits of
unimodality therapy in cases in which more aggressive
treatment cannot be tolerated. Outcomes for late-stage older
patients treated with unimodality therapy were statistically
superior to those who were not treated or who received
palliative care only.These data suggest that patient selection is
a more significant predictor of treatment tolerability and
oncologic outcomes than age alone and that age alone should
not preclude stage-appropriate multimodality therapy for
advanced head and neck cancer. These data may be useful to
patients and clinicians determining how aggressively to treat
patients aged.70years, given the lackofclinical trials focused
on this population.
Although oncologic outcomes in the elderly advanced
cancer group receiving unimodality therapy were superior to
no treatment or palliative treatment groups, such patients
had 5-year survival rates of 20%, almost half that of any other
group in the study. The reasons for such poor outcomes
were examined further in a retrospective chart review of
older patients with advanced laryngeal cancer treated with
unimodality therapy. Specifically, we sought to determine
whether receiving unimodality treatment was a function of
treatment bias, patient preference, or inability to tolerate
therapy. We noted that the majority of patients in this
subgroup had significant medical comorbidities. We also
demonstrated that the majority of these patients received an
initial treatment recommendation for multimodality therapy,
suggesting that elderly patients with advanced head and neck
cancer are routinely considered for multimodality treatment
without bias based on age. Despite this recommendation,
a significant percentage of patients declined a second
treatment modality. In addition, our review demonstrated
that nearly 20% of patients in this group died in the first 5
months after initiating treatment, underscoring the impact of
medical comorbidities and treatment toxicity on oncologic
outcomes in this population.
CONCLUSION
Our study confirmed age as an independent risk factor for
survival in patients treated with head and neck cancer. In
general, olderpatientswithstage Iand IIdiseasedid justaswell
as younger patients in terms of cancer outcomes, with the
modestly increased death rates of older patients apparently
attributable to competing causes ofmortality. In patients with
stage III and IV disease, those treated in a stage-appropriate
mannerwithmultimodality therapyhadoverall survival similar
to that of younger patients. Late-stage elderly patients treated
with unimodality therapy did very poorly. Most of these
patientswere initially recommended to receivemultimodality
therapy. Post hoc review of charts offered an initial hypothesis
that baseline comorbidities in these patients were high and
perhaps could have been used to predict patients who would
ultimately receive only one treatment modality. It is unknown
whether knowledge that a patient would receive only one
modalitymightalter the initial treatmentplanbutpresumably,
in some cases, it would. We believe this study highlights the
need for better understanding those factors, including
comorbidities and patient preference, that negatively affect
executionofplannedmultimodality therapy in advanced stage
head and neck cancer in elderly populations.
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